A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression

Oncogene

Volumn 34, Issue 50, 2015, Pages 6066-6078

  Salpeter, S J ^a   Pozniak, Y ^b   Merquiol, E ^a   Ben Nun, Y ^a   Geiger, T ^b   Blum, G ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; CYCLIN D1; CYCLIN D2; CYCLIN E; INTERLEUKIN 4; KI 67 ANTIGEN; REACTIVE OXYGEN METABOLITE; CATHEPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST TUMOR; CANCER REGRESSION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL POLARITY; DRUG EFFECTS; MACROPHAGE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; AUTOPHAGY; CATHEPSINS; CELL POLARITY; FEMALE; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84949534493     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.51     Document Type: Article

References (46)

1. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
2. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
3. Galdiero MR, Garlanda C, Jaillon S, Marone G, Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013; 228: 1404-1412.
4. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229: 176-185.
5. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9: 259-270.
6. White ES, Mantovani AR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. J Pathol 2013; 229: 141-144.
7. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012; 122: 787-795.
8. Vasiljeva O, Papazoglou A, Krüger A, Brodoefel H, Korovin M, Deussing J et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006; 66: 5242-5250.
9. Vasiljeva O, Korovin M, Gajda M, Brodoefel H, Bojic L, Krüger A et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008; 27: 4191-4199.
10. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13: 387-403.
11. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004; 385: 1017-1027.
12. Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML et al. Immunolocalization of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 1995; 83: 285-290.
13. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008; 29: 22-28.
14. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010; 24: 241-255.
15. Goulet B, Sansregret L, Leduy L, Bogyo M, Weber E, Chauhan SS et al. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 2007; 5: 899-907.
16. Goulet B, Baruch A, Moon NS, Poirier M, Sansregret LL, Erickson A et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol Cell 2004; 14: 207-219.
17. Concha C, Monardes A, Even Y, Morin V, Puchi M, Imschenetzky M et al. Inhibition of cysteine protease activity disturbs DNA replication and prevents mitosis in the early mitotic cell cycles of sea urchin embryos. J Cell Physiol 2005; 204: 693-703.
18. Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocyte-macrophage differentiation. Blood 2012; 119: 2895-2905.
19. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol Chem 2007; 388: 1141-1149.
20. Larghi P, Porta C, Riboldi E, Totaro MG, Carraro L, Orabona C et al. The p50 subunit of NF-κB orchestrates dendritic cell lifespan and activation of adaptive immunity. PLoS One 2012; 7: e45279.
21. Pello OM, Andrés V. Role of c-MYC in tumor-associated macrophages and cancer progression. Oncoimmunology 2013; 2: e22984.
22. Sevenich L, Schurigt U, Sachse K, Gajda M, Werner F, Müller S et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA 2010; 107: 2497-2502.
23. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res 2007; 67: 7378-7385.
24. Schurigt U, Sevenich L, Vannier C, Gajda M, Schwinde A, Werner F et al. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol Chem 2008; 389: 1067-1074.
25. Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol 2005; 1: 203-209.
26. Meara JP, Rich DH. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J Med Chem 1996; 39: 3357-3366.
27. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci USA 2009; 106: 14978-14983.
28. Hawker KM, Johnson PR, Hughes JM, Black JL. Interleukin-4 inhibits mitogeninduced proliferation of human airway smooth muscle cells in culture. Am J Physiol 1998; 275: L469-L477.
29. Hsu KF, Wu CL, Huang SC, Wu CM, Hsiao JR, Yo YT et al. Cathepsin L mediates resveratrol-induced autophagy and apoptotic cell death in cervical cancer cells. Autophagy 2009; 5: 451-460.
30. Dennemärker J, Lohmüller T, Müller S, Aguilar SV, Tobin DJ, Peters C et al. Impaired turnover of autophagolysosomes in cathepsin L deficiency. Biol Chem 2010; 391: 913-922.
31. Goulet B, Truscott M, Nepveu A. A novel proteolytically processed CDP/Cux isoform of 90 kDa is generated by cathepsin L. Biol Chem 2006; 387: 1285-1293.
32. Katunuma N. Posttranslational processing and modification of cathepsins and cystatins. J Signal Transduct 2010; 2010: 375345.
33. Pan L, Li Y, Jia L, Qin Y, Qi G, Cheng J et al. Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS One 2012; 7: e35315.
34. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab 2012; 15: 545-553.
35. Dragin N, Smani M, Arnaud-Dabernat S, Dubost C, Moranvillier I, Costet P et al. Acute oxidative stress is associated with cell proliferation in the mouse liver. FEBS Lett 2006; 580: 3845-3852.
36. Jacquel A, Obba S, Boyer L, Dufies M, Robert G, Gounon P et al. Autophagy is required for CSF-1-induced macrophagic differentiation and acquisition of phagocytic functions. Blood 2012; 119: 4527-4531.
37. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006; 5: 785-799.
38. Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res 2012; 72: 1199-1209.
39. Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie 2010; 92: 1618-1624.
40. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-2479.
41. Lin Y, Wei C, Liu Y, Qiu Y, Liu C, Guo F et al. Selective ablation of tumor-associated macrophages suppresses metastasis and angiogenesis. Cancer Sci 2013; 104: 1217-1225.
42. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009; 6: 359-362.
43. Winiewski JR, Zougman A, Mann M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res 2009; 8: 5674-5678.
44. Rappsilber J, Mann M, Ishihama Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protocols 2007; 2: 1896-1906.
45. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26: 1367-1372.
46. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activitybased probes. Nat Chem Biol 2007; 3: 668-677.